Antiphospholipid antibodies mediate autoimmunity against dying cells

Autoimmunity

Volumn 46, Issue 5, 2013, Pages 302-306

  Andreoli, Laura ^a   Fredi, Micaela ^a   Nalli, Cecilia ^a   Franceschini, Franco ^a   Meroni, Pier Luigi ^b   Tincani, Angela ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti domain antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Autoantibodies; Beta2glycoprotein I; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; EPITOPE; HLA ANTIGEN CLASS 2; PHOSPHOLIPID ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; AUTOIMMUNITY; CELL ACTIVATION; CELL DEATH; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PROCESSING; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; CELL DEATH; DISEASE MODELS, ANIMAL; HUMANS;

EID: 84880360468     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2013.783025     Document Type: Review

References (42)

1. Miyakis, S., M. D. Lockshin, T. Atsumi, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost 4: 295-306
2. Meroni, P. L., M. O. Borghi, E. Raschi, and F. Tedesco. 2011. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat. Rev. Rheumatol 7: 330-339
3. Giannakopoulos, B., P. Mirarabshahi, and S. A. Krilis. 2011. New insights into the biology and pathobiology of beta2- glycoprotein I. Curr. Rheumatol. Rep 13: 90-95
4. Agar, C., G. M. van Os, M. Mörgelin, et al. 2010. Beta2- glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome. Blood 116: 1336-1343
5. Agar, C., P. G. de Groot, M. Mörgelin, et al. 2011. bglycoprotein I: A novel component of innate immunity. Blood 117: 6939-6947
6. Price, B. E., J. Rauch, M. A. Shia, et al. 1996. Antiphospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J. Immunol 157: 2201-2208
7. Maiti, S. N., K. Balasubramanian, J. A. Ramoth, and A. J. Schroit. 2008. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptorrelated protein receptor family members. J. Biol. Chem 283: 3761-3766
8. Rauch, J., M. Dieudé, R. Subang, and J. S. Levine. 2010. The dual role of innate immunity in the antiphospholipid syndrome. Lupus 19: 347-353
9. Levine, J. S., J. S. Koh, R. Subang, and J. Rauch. 1999. Apoptotic cells as immunogen and antigen in the antiphospholipid syndrome. Exp. Mol. Pathol 66: 82-98
10. Bondanza, A., P. Rovere-Querini, V. S. Zimmermann, et al. 2007. Requirement for dendritic cells in the establishment of anti-phospholipid antibodies. Autoimmunity 40: 302-306
11. Bondanza, A., V. S. Zimmermann, G. Dell'Antonio, et al. 2004. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum 50: 1549-1560
12. Kuwana, M., E.Matsuura, K. Kobayashi, et al. 2005. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 105: 1552-1557
13. Tolomeo, T., A. Rico De Souza, E. Roter, et al. 2009. T cells demonstrate a Th1-biased response to native beta2-glycoprotein I in a murine model of anti-phospholipid antibody induction. Autoimmunity 42: 292-295
14. Manfredi, A. A., P. Rovere, G. Galati, et al. 1998. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 41: 205-214
15. Manfredi, A. A., P. Rover, S. Heltai, et al. 1998. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2- glycoprotein I. Arthritis Rheum 41: 215-223
16. Rovere, P., A. A.Manfredi, C. Vallinoto, et al. 1998. Dendritic cells preferentially internalize apoptotic cells opsonized by anti-beta2-glycoprotein I antibodies. J. Autoimmun 11: 403-411
17. Rovere, P., M. G. Sabbadini, C. Vallinoto, et al. 1999. Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: Role of opsonizing anti-beta2- glycoprotein I antibodies. Arthritis Rheum 42: 1412-1420
18. Michlewska, S., A. McColl, A. G. Rossi, I. L. Megson, and I. Dransfield. 2007. Clearance of dying cells and autoimmunity. Autoimmunity 40: 267-273
19. Patel, V. A., A. Longacre-Antoni, M. Cvetanovic, et al. 2007. The affirmative response of the innate immune system to apoptotic cells. Autoimmunity 40: 274-280
20. Sarmiento, L. F., L. E. Muñoz, P. Chirinos, N. E. Bianco, and M. E. Zabaleta-Lanz. 2007. Opsonization by anti-dsDNA antibodies of apoptotic cells in systemic lupus erythematosus. Autoimmunity 40: 337-339
21. Kajiwara, T., T. Yasuda, and E. Matsuura. 2007. Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. J. Autoimmun 29: 164-173
22. Matsuura, E., G. R. V. Hughes, and M. A. Khamashta. 2008. Oxidation of LDL and its clinical implication. Autoimmun. Rev 7: 558-566
23. Fürnrohr, B. G., G. J. Groer, B. Sehnert, M. Herrmann, and R. E. Voll. 2007. Interaction of histones with phospholipids- implications for the exposure of histones on apoptotic cells. Autoimmunity 40: 322-326
24. Reed, J. H., B. Giannakopoulos, M. W. Jackson, S. A. Krilis, and T. P. Gordon. 2009. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum 60: 860-869
25. Arbuckle, M. R., M. T. McClain, M. V. Rubertone, et al. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med 349: 1526-1533
26. Levine, J. S., R. Subang, S.H. Nasr, et al. 2006. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J. Immunol 177: 6504-6516
27. Andreoli, L., F. Pregnolato, R. W. Burlingame, et al. 2008. Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity? J. Autoimmun 30: 51-57
28. Tincani, A., L. Andreoli, C. Chighizola, and P. L. Meroni. 2009. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 42: 257-259
29. Heyder, P., I. Bekeredjian-Ding, M. Parcina, et al. 2007. Purified apoptotic bodies stimulate plasmacytoid dendritic cells to produce IFN-Alpha. Autoimmunity 40: 331-332
30. Sozzani, S., D. Bosisio,M. Scarsi, and A. Tincani. 2010. Type I interferons in systemic autoimmunity. Autoimmunity 43: 196-203
31. Shoenfeld, Y., P. L. Meroni, and E. Toubi. 2009. Antiphospholipid syndrome and systemic lupus erythematosus: Are they separate entities or just clinical presentations on the same scale? Curr. Opin. Rheumatol 21: 495-500
32. Yin, H., M. O. Borghi, A. M. Delgado-Vega, et al. 2009. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 60: 2468-2471
33. Fredi, M., A. Tincani, H. Yin, et al. 2010. IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis Rheum 62: 1201-1202
34. Sebastiani, G.,G. Minisola, and M. Galeazzi. 2003. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun. Rev 2: 387-394
35. Chamorro, A. J., M. Marcos, J. A. Mirón-Canelo, R. Cervera, and G. Espinosa. 2012. Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-Analysis. Autoimmun. Rev 11: 705-712
36. Lockshin, M. D., and J. E. Salmon. 2011. Are posttranslational modifications of b2-glycoprotein I markers for thrombotic risk? Are they triggers of autoimmunity? Arthritis Rheum 63: 2558-2560
37. Ioannou, Y., J. Y. Zhang, M. Qi, et al. 2011. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen b2-glycoprotein I. Arthritis Rheum 63: 2774-2782
38. de Laat, B., V. Pengo, I. Pabinger, et al. 2009. The association between circulating antibodies against domain I of beta2- glycoprotein I and thrombosis: An international multicenter study. J. Thromb. Haemost 7: 1767-1773
39. Andreoli, L., C. Nalli, M. Motta, et al. 2011. Antib- glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: Might it be the reason for their 'innocent' profile? Ann. Rheum. Dis 70: 380-383
40. de Laat, B., M. van Berkel, R. T. Urbanus, et al. 2011. Immune responses against domain I of b(2)-glycoprotein I are driven by conformational changes: Domain I of b(2)- glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 63: 3960-3968
41. Agostinis, C., S. Biffi, C. Garrovo, et al. 2012. In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions. Blood 2011 118: 4231-4238
42. Böhm, S., I. Schwab, A. Lux, and F. Nimmerjahn. 2012. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin. Immunopathol 34: 443-453